M&A / Deals Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss pharminent May 27, 2026
Clinical Data Early data for heart drug affirm Lilly’s billion-dollar bet on Verve pharminent May 26, 2026
Clinical Data Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study pharminent May 26, 2026
Clinical Data Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival pharminent May 22, 2026
M&A / Deals Gilead inks $140M API supply deal, tightening ties to Korean manufacturer pharminent May 22, 2026
Clinical Data Lilly’s triple agonist shows bariatric surgery-like weight loss results pharminent May 21, 2026
M&A / Deals Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling pharminent May 21, 2026
Clinical Data BioMarin bounces back as Voxzogo performs ‘bigger than expected’ in new indication pharminent May 21, 2026
Clinical Data ATS 2026: PABPC4 gene identified as a key driver of emphysema in COPD pharminent May 21, 2026
Clinical Data ATS 2026: Long-term data show durable benefit of Trikafta for cystic fibrosis pharminent May 21, 2026
Pipeline Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update pharminent May 20, 2026
Regulatory Pazdur declines to announce candidacy for vacated FDA commissioner role pharminent May 20, 2026
Clinical Data Beam one-ups Wave as both show promise of genetic editing for AATD pharminent May 20, 2026
Clinical Data AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis pharminent May 20, 2026
Clinical Data Relay doubles the bar, outpacing Novartis with a 60% response in rare disease pharminent May 19, 2026
Clinical Data Relay drug shows early promise against rare blood vessel diseases pharminent May 19, 2026
Clinical Data BioMarin suffers another blow to rare disease portfolio in Phase 3 flop pharminent May 19, 2026
Clinical Data UCB reports positive outcomes for bimekizumab in psoriatic arthritis pharminent May 19, 2026
Regulatory VERTANICAL’s VER-01 gains FDA breakthrough status for low back pain pharminent May 19, 2026
M&A / Deals Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates pharminent May 19, 2026
